as per annexure enclosed
Awaiting price reaction for this filing.
Apollo Hospitals reported strong FY25 results with consolidated revenue of ₹21,794 crore (up 14% YoY), EBITDA of ₹3,022 crore (up 26%), and PAT of ₹1,446 crore (up 61%). Q4 FY25 alone saw revenue of ₹5,592 crore (up 13%), EBITDA of ₹770 crore (up 20%), and PAT of ₹390 crore (up 54%). The Healthcare Services (Hospitals) segment posted healthy growth with bed occupancy improving to 67% in Q4 (from 65%), ARPOB rising 7% to ₹63,569/day, and EBITDA margin expanding to 24.3% from 23.1%. HealthCo turned profitable at the PAT level for the first full year (₹47 crore vs ₹196 crore loss in FY24) after cost optimization. The company completed ₹2,475 crore investment from Advent International into Apollo HealthCo and proposed merging Keimed (pharma distribution major) with HealthCo, targeting combined Year 3 revenues of ~₹25,000 crore with 7-8% operating margins. Expansion plan covers 4,372 new beds across India with a total project cost of ₹8,094 crore.
Strong margin expansion and PAT growth in core hospital business, combined with HealthCo turning profitable and large private equity backing, signals improving business momentum. The Keimed merger is expected to be EPS accretive from Year 1, and the multi-year expansion plan supports future revenue growth — likely positive for the stock.